1. AngioDynamics enrolled the first patient in a critical study of Auryon atherectomy. 2. The study compares Auryon plus angioplasty to angioplasty alone for treating patients.
The initiation of this trial indicates ongoing innovation and potential revenue growth, similar to previous positive study results boosting stock prices.
This development signifies AngioDynamics’ commitment to innovation, potentially driving future sales and investor confidence.
Successful trial results can lead to market expansion and increased sales over time, as evidenced by past product approvals enhancing company performance.